3 results
Approved WMOCompleted
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
Approved WMOCompleted
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
Approved WMOCompleted
To assess the efficacy and patient safety of (1)fractional laser treatment in combination with NB- UVB,(2) fractional laser treatment in combination with NB- UVB and topical corticosteroids versus NB-UVB treatment alone.